Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

681. Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search (...) Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation 1 October 2008 Article Contents Article Navigation Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline James L. Rosenzweig 1 Boston Medical Center and Boston University School of Medicine (J.L.R.), Boston, Massachusetts 02118 * Address all

The Endocrine Society2008

682. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs.

Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. In 2005, a global goal of reducing chronic disease death rates by an additional 2% per year was established. Scaling up coverage of evidence-based interventions to prevent cardiovascular disease in high-risk individuals in low-income and middle-income countries could play a major part in reaching this goal. We aimed to estimate the number of deaths that could (...) be averted and the financial cost of scaling up, above current coverage levels, a multidrug regimen for prevention of cardiovascular disease (a statin, aspirin, and two blood-pressure-lowering medicines) in 23 such countries. Identification of individuals was limited to those already accessing health services, and treatment eligibility was based on the presence of existing cardiovascular disease or absolute risk of cardiovascular disease by use of easily measurable risk factors. Over a 10-year period

Lancet2007

683. Prevention of secondary disease: lipid screening and cardiovascular risk.

Prevention of secondary disease: lipid screening and cardiovascular risk. Prevention of secondary disease: lipid screening and cardiovascular risk. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:005743 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information

New York State Department of Health2007

684. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study BACKGROUND: The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported. OBJECTIVE: To assess the cost effectiveness of perindopril in stable coronary heart disease in the UK. METHODS: Clinical and resource use data were taken from the EUROPA trial. Costs included drugs (...) and hospitalisations. Health-related quality of life values were taken from published sources. A cost-effectiveness analysis is presented as a function of the risk of a primary event (non-fatal myocardial infarction, cardiac arrest or cardiovascular death) in order to identify people for whom treatment offers greatest value for money. RESULTS: The median incremental cost of perindopril for each quality-adjusted life year (QALY) gained across the heterogeneous population of EUROPA was estimated as 9700 pounds

EvidenceUpdates2007 Full Text: Link to full Text with Trip Pro

685. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. OBJECTIVE: To derive a new cardiovascular disease risk score (QRISK) for the United Kingdom and to validate its performance against the established Framingham cardiovascular disease algorithm and a newly developed Scottish score (ASSIGN). DESIGN: Prospective open cohort study using routinely collected data from general practice. SETTING: UK practices contributing (...) to the QRESEARCH database. PARTICIPANTS: The derivation cohort consisted of 1.28 million patients, aged 35-74 years, registered at 318 practices between 1 January 1995 and 1 April 2007 and who were free of diabetes and existing cardiovascular disease. The validation cohort consisted of 0.61 million patients from 160 practices. MAIN OUTCOME MEASURES: First recorded diagnosis of cardiovascular disease (incident diagnosis between 1 January 1995 and 1 April 2007): myocardial infarction, coronary heart disease

BMJ2007 Full Text: Link to full Text with Trip Pro

686. Dietary glycemic index, dietary glycemic load, and cardiovascular disease in middle-aged and older Swedish men.

Dietary glycemic index, dietary glycemic load, and cardiovascular disease in middle-aged and older Swedish men. BACKGROUND: In women, dietary glycemic index (GI) and dietary glycemic load (GL) have been associated with cardiovascular disease; in men, however, the evidence for an association is weaker. OBJECTIVE: We tested the hypothesis that men consuming diets high in GI or GL have a greater risk of cardiovascular disease. DESIGN: At baseline, we assessed dietary GI and dietary GL by using (...) food-frequency questionnaires in 36 246 Swedish men aged 45-79 y without diabetes or prior cardiovascular disease. Participants were followed through inpatient, cause-of-death, and death registries from 1 January 1998 until 31 December 2003 for myocardial infarction, ischemic stroke, hemorrhagic stroke, and cardiovascular mortality and until 31 December 2005 for all-cause mortality. We used Cox models with age as the time scale to estimate relative risks adjusted for cigarette smoking

EvidenceUpdates2007 Full Text: Link to full Text with Trip Pro

687. Does a diagnosis of the metabolic syndrome provide additional prediction of cardiovascular disease and total mortality in the elderly? The Dubbo Study

Does a diagnosis of the metabolic syndrome provide additional prediction of cardiovascular disease and total mortality in the elderly? The Dubbo Study OBJECTIVE: To assess whether a diagnosis of the metabolic syndrome (MetS) improves the prediction of cardiovascular disease or total mortality beyond that already provided by conventional risk factors. DESIGN AND SETTING: A longitudinal cohort study conducted in Dubbo, New South Wales. PARTICIPANTS: 2805 men and women aged 60 years and older (...) living in the community, first assessed in 1988-1989 and followed for 16 years. MAIN OUTCOME MEASURES: Coronary heart disease (CHD) events, ischaemic stroke events, and total mortality. RESULTS: MetS was present in 31% of men and 34% of women. Crude CHD, ischaemic stroke, and total mortality rates were higher in the presence of MetS in men and women. In proportional hazards models that included conventional risk factors, but excluded variables used to define the presence of MetS, MetS

EvidenceUpdates2007

688. Role of clopidogrel in managing atherothrombotic cardiovascular disease.

Role of clopidogrel in managing atherothrombotic cardiovascular disease. Aspirin is the most widely used antiplatelet agent for preventing and treating vascular events. The thienopyridine derivatives, ticlopidine and clopidogrel, are a suitable alternative in patients who are intolerant to aspirin, and clopidogrel exhibits better tolerability than ticlopidine. The available evidence from randomized trials indicates that dual therapy with clopidogrel and aspirin is modestly but significantly (...) more effective than aspirin in preventing serious vascular events. It is also associated with a favorable benefit-risk profile in patients at high risk (especially in acute coronary syndromes and after stenting). In patients at low risk (stable cardiovascular disease), however, the bleeding risk of dual therapy exceeds its potential benefit. The dose and duration of pretreatment before stenting, the optimal duration of treatment after drug-eluting stent implantation, concurrent administration

Annals of Internal Medicine2007

689. Vitamin E did not prevent cardiovascular disease and cancer in healthy women

Vitamin E did not prevent cardiovascular disease and cancer in healthy women Vitamin E did not prevent cardiovascular disease and cancer in healthy women | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Vitamin E did not prevent cardiovascular disease and cancer in healthy women Article Text Therapeutics Vitamin E did not prevent cardiovascular disease and cancer in healthy women Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below

Evidence-Based Medicine (Requires free registration)2007

690. Risk estimation and the prevention of cardiovascular disease

Risk estimation and the prevention of cardiovascular disease

SIGN2007

691. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.

N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. CONTEXT: Identification of individuals at high risk for cardiovascular events is important for the optimal use of primary and secondary prevention measures. OBJECTIVE: To determine whether plasma levels of amino terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) predict cardiovascular events or death (...) independent of other available prognostic tests. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study (2000-2002) of 987 individuals in California with stable coronary heart disease in the Heart and Soul Study, who were followed up for a mean of 3.7 (range, 0.1-5.3) years. MAIN OUTCOME MEASURES: The association of baseline NT-proBNP levels with death or cardiovascular events (myocardial infarction, stroke, or heart failure). Traditional clinical risk factors, echocardiographic measures, ischemia

JAMA2007 Full Text: Link to full Text with Trip Pro

692. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials

Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Helton T J, Bavry A A, Kumbhani D J, Duggal S, Roukoz H, Bhatt D L CRD summary The authors (...) concluded that the addition of clopidogrel to aspirin slightly reduces all-cause and cardiovascular mortality in patients with ST-elevation myocardial infarction (STEMI), and modestly reduces myocardial infarction and stroke in patients with cardiovascular disease, but also increases bleeding. The review was generally well-conducted, but the lack of results data undermines the conclusion about the subgroup of STEMI patients. The other conclusions appear reliable. Authors' objectives To compare

DARE.2007

693. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials

Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular (...) function: a pooled meta-analysis of randomized placebo-controlled trials Saha SA, Molnar J, Arora RR CRD summary The review concluded that tissue angiotensin-converting enzyme inhibitors demonstrated benefit when used for secondary prevention of cardiovascular disease in patients with preserved left ventricular function in randomised placebo-controlled trials. The authors’ conclusion represented the evidence presented, but lack of clarity about review methods means that their reliability is unclear

DARE.2007

694. Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases

Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases Annemans L, Lamotte M, Clarys P, Van den Abeele E Record Status (...) of cardiovascular events; the percentage of fatal coronary heart disease (CHD) and cerebrovascular disease; the annual risk of nonfatal stroke, myocardial infarction (MI) and death given a previous history of either MI or stroke; the relative risk for CHD and cerebrovascular disease with exercise; the risk of colon and breast cancer; the survival rates for breast and colon cancer; the relative risk for breast and colon cancer with exercise; the incidence of diabetes; the relative risk for diabetes with exercise

NHS Economic Evaluation Database.2007

695. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study Briggs A, Mihaylova B, Sculpher M, Hall (...) of cardiovascular events in patients with stable coronary artery disease. Treatment was assumed to last 5 years or until patient death. Perindopril was compared with placebo. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a cohort of patients with stable coronary heart disease without apparent heart failure or hypertension (low-risk patients). Setting The setting was secondary care. The economic study was carried out

NHS Economic Evaluation Database.2007

696. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin (...) atorvastatin treatment, at doses of 10 mg daily, with placebo for the primary prevention of cardiovascular disease (CVD) in patients with Type 2 diabetes. Data from the Collaborative Atorvastatin Diabetes Study (CARDS) were used (Colhoun et al. 2004, see 'Other Publications of Related Interest' below for bibliographic details). Besides evaluating global differences, the study also evaluated the effects in three patient risk groups within the trial. Type of intervention Primary prevention. Economic study

NHS Economic Evaluation Database.2007

697. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan

A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of low-dose aspirin (100 mg/day) as primary prevention in patients at increased risk of cardiovascular disease (CVD). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical

NHS Economic Evaluation Database.2007

698. Aspirin for the primary prevention of cardiovascular disease in women

Aspirin for the primary prevention of cardiovascular disease in women Aspirin for the primary prevention of cardiovascular disease in women Aspirin for the primary prevention of cardiovascular disease in women Pignone M, Earnshaw S, Pletcher M J, Tice J A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The study examined low-dose aspirin (100 mg every other day) for the primary prevention of cardiovascular disease in women. The comparator was no aspirin. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of women at "moderate risk" of cardiovascular disease. Specifically, 65-year-old women with the following risk factor profile

NHS Economic Evaluation Database.2007

699. Statins in primary prevention of cardiovascular disease - Is used based on real evidence or distorted evidence?

Statins in primary prevention of cardiovascular disease - Is used based on real evidence or distorted evidence? Volumen 15. DTB Navarre. Vol 15, No 1. January - February 2007 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DTB Navarre. Vol 15, No 1. January - February 2007 DTB Navarre. Vol 15, No 1. January - February 2007 Content tools Share it Statins in primary prevention of cardiovascular disease: Is use based on real evidence (...) or distorted evidence? Over the last few years the statins has become the highest consumption therapeutic group within the Navarre Regional Health Service as well as in the rest of Spain. The increasing media impact on the population at large and on the medical profession has created an impression of illness where there is simply a risk factor. The Spanish epidemiology reality differs notably from the circumstances of actual clinical testing with statins. Critical appraisal of the different clinical trials

Drug and Therapeutics Bulletin of Navarre (Spain)2007

700. An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in obese participants with type 2 diabetes at 1 year in an interim analysis

An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in obese participants with type 2 diabetes at 1 year in an interim analysis An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in obese participants with type 2 diabetes at 1 year in an interim analysis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in obese participants with type 2 diabetes at 1 year in an interim analysis Article Text

Evidence-Based Medicine (Requires free registration)2007